Capsaicin Effect on Cytokines Profile in Dyslipidemia


The increased mortality from cardiovascular disease has a significant impact on the population, and the prevalence of these diseases it become one of the major problems, since it is the leading cause of mortality and 1 in 3 Mexicans suffer from cardiovascular disease according ENSANUT; the above is attributed to the increase of diseases associated with an inflammatory process accelerated as obesity, dyslipidemia, hypertension (SAH) and diabetes mellitus (DM). The cholesterol is a major risk factor in the development of cardiovascular disease, and in turn increases the chances of death; however, the treatment of choice is based on changes in lifestyle, which for most people are difficult to maintain long-term. As for the drug therapy treated with drugs many people do not achieve their therapeutic goals, and therefore the inflammatory condition that underlies this disease remains. Recent studies have focused on the possible role of capsaicin in the inflammatory state through the agonistic effect it has on TRPV1. It has demonstrated the antiinflammatory activity of capsaicin to enhance inflammation by free fatty acids (FFA) and reducing the expression of certain genes involved in this process induced. Capsaicin is a natural choice and well tolerated with few side effects limited to the gastrointestinal tract such as dyspepsia and intestinal irregularity, for the above is of interest to evaluate the effect of capsaicin on the profile of inflammatory cytokines in individuals with dyslipidemia.

Full Title of Study: “Effect of Administration of Capsaicin on Inflammatory Cytokines Profile(TNFα , IL – 1β , IL – 6, IL -8 , MIP – 1β) in Individuals With Dyslipidemia.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: April 2017

Detailed Description

It will conduct a clinicala trial, double – blind, randomized and placebo control group. Female and male patients, with dyslipidemia. Two groups will be formed with 17 patients each (capsaicin 150 mg per day or Magnesia calcinada). At the beginning and end of the intervention clinical and laboratory determination. The data obteined were analyzed using SPSS statistical software version 22. It was considered statistically significant at p <0.05


  • Drug: Capsaicin
  • Drug: Magnesia calcinada

Arms, Groups and Cohorts

  • Experimental: Capsaicin
    • 75 mg capsaicin every 12 hours for 90 days
  • Placebo Comparator: Control
    • 75 mg magnesia calcinada every 12 hours for 90 days

Clinical Trial Outcome Measures

Primary Measures

  • Inflammatory cytokines profile
    • Time Frame: 90 days
    • TNFα
  • Inflammatory cytokines profile
    • Time Frame: 90 days
    • IL-1β
  • Inflammatory cytokines profile
    • Time Frame: 90 days
    • IL-6
  • Inflammatory cytokines profile
    • Time Frame: 90 days
    • IL-8
  • Inflammatory cytokines profile
    • Time Frame: 90 days
    • MIP-1β

Secondary Measures

  • Lipids profile
    • Time Frame: 90 days
    • total cholesterol
  • Lipids profile
    • Time Frame: 90 days
    • triglycerides
  • Lipids profile
    • Time Frame: 90 days
    • C-HDL
  • Lipids profile
    • Time Frame: 90 days
    • C-LDL
  • Lipids profile
    • Time Frame: 90 days
    • C-VLDL

Participating in This Clinical Trial

Inclusion Criteria

  • diagnosis of dyslipidemia at the time of screening – BMI of 25 kg /m2 to 34.9 kg / m2 – Without drug treatment in the last three months – Signature of consent information in writing Exclusion Criteria:

  • Pregnant or lactating – Total cholesterol ≥ 239 mg / dL, ≥400 TG, LDL-C ≥139 – Other inflammatory diseases – consumption of some type of supplement – Diagnosis or history of kidney or liver disease ∞ History of hypersensitivity to the compounds used in the study

Gender Eligibility: All

Minimum Age: 25 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Guadalajara
  • Collaborator
    • PhD. Teresa Arcelia Garcia Cobian
  • Provider of Information About this Clinical Study
    • Principal Investigator: Ernesto Javier Ramirez Lizardo, PhD. – University of Guadalajara
  • Overall Official(s)
    • Ernesto J Ramirez Lizardo, PhD, Principal Investigator, University Guadalajara
  • Overall Contact(s)
    • Leonel Garcia Benavides, PhD, 10585200,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.